Who are Bicillin C-R's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bicillin C-R, Bicillin C-R, Amoxil, ceftriaxone sodium + metronidazole, Vonoprazan+amoxicillin+clarithromycin 14 days, piperacillin extended infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bicillin-c-r.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Bicillin C-R — Competitive Intelligence Brief

Bicillin C-R (Penicillin G Benzathine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic. Area: Metabolic.

marketed Beta-lactam antibiotic Cell-wall peptidoglycan biosynthesis Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Bicillin C-R (Penicillin G Benzathine) — Pfizer Inc.. Penicillin G inhibits bacterial cell-wall peptidoglycan biosynthesis, rendering the cell wall osmotically unstable.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bicillin C-R TARGET	Penicillin G Benzathine	Pfizer Inc.	marketed	Beta-lactam antibiotic	Cell-wall peptidoglycan biosynthesis
Bicillin C-R	Penicillin G Benzathine	Pfizer	marketed	Beta-lactam antibiotic	Cell-wall peptidoglycan biosynthesis	1952-01-01
Bicillin C-R	Penicillin G Benzathine	Pfizer	marketed	Beta-lactam antibiotic	Cell-wall peptidoglycan biosynthesis	1952-01-01
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	marketed	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
ceftriaxone sodium + metronidazole	ceftriaxone sodium + metronidazole	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Beta-lactam antibiotic + nitroimidazole antibiotic combination	Bacterial penicillin-binding proteins (ceftriaxone); anaerobic bacterial DNA (metronidazole)
Vonoprazan+amoxicillin+clarithromycin 14 days	Vonoprazan+amoxicillin+clarithromycin 14 days	Xijing Hospital of Digestive Diseases	marketed	Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) + macrolide antibiotic (clarithromycin)	H+/K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)
piperacillin extended infusion	piperacillin extended infusion	University Hospital, Ghent	marketed	Beta-lactam antibiotic (ureidopenicillin)	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-12-08 — Amoxil · 8778924 · Compound · US
2026-12-08 — Amoxil · 8357394 · Formulation · US
2027-05-07 — Amoxil · 8299052 · Method of Use · US

Sponsor landscape (Beta-lactam antibiotic class)

Pfizer · 2 drugs in this class
Bayer · 1 drug in this class
Belén Retamal-Valdes · 1 drug in this class
Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 drug in this class
Esraa Salah Mohamed Abdallah Eladl · 1 drug in this class
Incheon St.Mary's Hospital · 1 drug in this class
International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 drug in this class
KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bicillin C-R — Competitive Intelligence Brief. https://druglandscape.com/ci/bicillin-c-r. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab